Related Experiment Video
Updated: Jun 8, 2026
05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
[Recent progress and novel perspectives on obesity pharmacotherapy]
André M Faria1, Marcio C Mancini, Maria Edna de Melo
1Hospital das Clínicas, Universidade de São Paulo, SP, Brasil.
Arquivos Brasileiros De Endocrinologia E Metabologia
|September 22, 2010
Summary
Obesity is a growing health crisis. This review explores new weight-loss drugs and combination therapies, offering hope beyond lifestyle changes and surgery.
Area of Science:
- Pharmacology and Endocrinology
- Metabolic Diseases
- Cardiovascular Health
Context:
- Rising global obesity rates present significant metabolic and cardiovascular risks.
- Lifestyle modifications alone offer modest long-term weight loss efficacy.
- Bariatric surgery is effective but carries potential complications; current pharmacotherapy options are limited.
Purpose:
- To review recent clinical trial data on novel anti-obesity pharmacotherapies.
- To assess the efficacy and safety profiles of emerging weight-loss medications.
- To discuss combination therapies for enhanced weight management.
Summary:
- Examines novel drugs like lorcaserin, tesofensine, liraglutide, and cetilistat.
- Discusses combination therapies including bupropion/naltrexone and phentermine/topiramate.
- Highlights recent advancements in pharmacotherapy for obesity treatment.
Impact:
- Provides insights into potential new treatments for obesity.
- Informs clinicians and researchers about emerging anti-obesity agents.
- Contributes to the understanding of pharmacological approaches to managing obesity and its complications.
Related Concept Videos
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
01:24Obesity
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
01:21Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...